secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2026-08-06T11:05:06+00:00
Accession:  0001193125-26-336691
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian reports Q2 net loss of $127M; Lumvoa FDA-approved and launched in June
-------------------------------------------------------------------------------

- Lumvoa (veligrotug-vvze) approved by FDA for thyroid eye disease on June 26, 2026, and immediately launched in U.S.
- Elegrobart BLA submission on track for Q1 2027; phase 3 trials showed robust proptosis reduction.
- Cash, cash equivalents, and marketable securities of $981.5M as of June 30, 2026, up from $762.2M at March 31, 2026.
- Net loss for Q2 2026 was $127.1M, compared to $100.7M in Q2 2025; R&D expenses decreased to $71.6M from $86.6M.
- Completed convertible debt and equity financing in May 2026 with gross proceeds of $394M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/0001193125-26-336691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer